KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Investing Activities (2016 - 2025)

Pfizer (PFE) has disclosed Cash from Investing Activities for 17 consecutive years, with -$6.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 278.68% to -$6.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.4 billion, a 150.94% decrease, with the full-year FY2025 number at -$1.4 billion, down 150.94% from a year prior.
  • Cash from Investing Activities was -$6.1 billion for Q4 2025 at Pfizer, down from -$2.4 billion in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $4.6 billion in Q2 2024 to a low of -$25.5 billion in Q3 2023.
  • A 5-year average of -$4.6 billion and a median of -$1.9 billion in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 2359.15% in 2021, then surged 484.66% in 2023.
  • Pfizer's Cash from Investing Activities stood at -$20.0 billion in 2021, then skyrocketed by 43.02% to -$11.4 billion in 2022, then rose by 3.31% to -$11.0 billion in 2023, then soared by 85.24% to -$1.6 billion in 2024, then crashed by 278.68% to -$6.1 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Cash from Investing Activities are -$6.1 billion (Q4 2025), -$2.4 billion (Q3 2025), and $4.0 billion (Q2 2025).